IBD and pregnancy : From conception to birth
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
Inflammatory Bowel Diseases (IBD) are chronic conditions affecting young people in their reproductive age. Patient misinformation can be responsible for a self-imposed infertility as well as a suboptimal observance during pregnancy. The aim of this work was to review the influence of IBD and pregnancy on one another at each gestational stage and according to current literature. IBD activity is a major influential factor. In case of a well-controlled IBD, fertility won't be affected and pregnancy will take place without increase risk of complications. With the exception of thalidomide and methotrexate, most of treatments used in IBD are compatible with pregnancy and breastfeeding. Each flare should be optimally managed. Vaginal delivery is a safe option except for patients with active anoperineal lesions. Cesarean section should be systematically discuss in patient with ileal pouch-anal anastomosis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
---|---|
Enthalten in: |
Gynecologie, obstetrique, fertilite & senologie - 48(2020), 6 vom: 28. Juni, Seite 514-519 |
Sprache: |
Französisch |
---|
Weiterer Titel: |
Maladie chronique inflammatoire de l’intestin et grossesse : de la conception à la naissance |
---|
Beteiligte Personen: |
Foulon, A [VerfasserIn] |
---|
Links: |
---|
Themen: |
4Z8R6ORS6L |
---|
Anmerkungen: |
Date Completed 18.06.2021 Date Revised 18.06.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.gofs.2020.02.013 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM307338525 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM307338525 | ||
003 | DE-627 | ||
005 | 20231225125340.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||fre c | ||
024 | 7 | |a 10.1016/j.gofs.2020.02.013 |2 doi | |
028 | 5 | 2 | |a pubmed24n1024.xml |
035 | |a (DE-627)NLM307338525 | ||
035 | |a (NLM)32145453 | ||
035 | |a (PII)S2468-7189(20)30089-1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a fre | ||
100 | 1 | |a Foulon, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a IBD and pregnancy |b From conception to birth |
246 | 3 | 3 | |a Maladie chronique inflammatoire de l’intestin et grossesse : de la conception à la naissance |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.06.2021 | ||
500 | |a Date Revised 18.06.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
520 | |a Inflammatory Bowel Diseases (IBD) are chronic conditions affecting young people in their reproductive age. Patient misinformation can be responsible for a self-imposed infertility as well as a suboptimal observance during pregnancy. The aim of this work was to review the influence of IBD and pregnancy on one another at each gestational stage and according to current literature. IBD activity is a major influential factor. In case of a well-controlled IBD, fertility won't be affected and pregnancy will take place without increase risk of complications. With the exception of thalidomide and methotrexate, most of treatments used in IBD are compatible with pregnancy and breastfeeding. Each flare should be optimally managed. Vaginal delivery is a safe option except for patients with active anoperineal lesions. Cesarean section should be systematically discuss in patient with ileal pouch-anal anastomosis | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Crohn disease | |
650 | 4 | |a Fertility | |
650 | 4 | |a Fertilité | |
650 | 4 | |a Grossesse | |
650 | 4 | |a Maladie de Crohn | |
650 | 4 | |a Pregnancy | |
650 | 4 | |a Rectocolite hémorragique | |
650 | 4 | |a Ulcerative colitis | |
650 | 7 | |a Thalidomide |2 NLM | |
650 | 7 | |a 4Z8R6ORS6L |2 NLM | |
650 | 7 | |a Methotrexate |2 NLM | |
650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
700 | 1 | |a Chevreau, J |e verfasserin |4 aut | |
700 | 1 | |a Yzet, C |e verfasserin |4 aut | |
700 | 1 | |a Gondry, J |e verfasserin |4 aut | |
700 | 1 | |a Fumery, M |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Gynecologie, obstetrique, fertilite & senologie |d 2017 |g 48(2020), 6 vom: 28. Juni, Seite 514-519 |w (DE-627)NLM269302743 |x 2468-7189 |7 nnns |
773 | 1 | 8 | |g volume:48 |g year:2020 |g number:6 |g day:28 |g month:06 |g pages:514-519 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gofs.2020.02.013 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 48 |j 2020 |e 6 |b 28 |c 06 |h 514-519 |